Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vactosertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 known ✓ | P36897 | 20/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 18/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | TGFB1 | P01137 | 1/20 | 1.00 |
| ▸ | KDR | P35968 | 1/20 | 1.00 |
| ▸ | ACVR1B | P36896 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vactosertib SCHEMBL29508696 | 1.00 | TGFBR1 (1.00) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| Vactosertib SCHEMBL29352498 | 1.00 | TGFBR1 (1.00) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| Vactosertib SCHEMBL29493095 | 1.00 | TGFBR1 (1.00) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| SCHEMBL248684 | 0.94 | TGFBR1 (1.00) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| Vactosertib SCHEMBL26345807 | 0.93 | TGFBR1 (0.87) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| Vactosertib SCHEMBL30568127 | 0.93 | TGFBR1 (0.87) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| SCHEMBL248262 | 0.91 | TGFBR1 (1.00) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| SCHEMBL19492123 | 0.91 | TGFBR1 (0.83) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| SCHEMBL249547 | 0.90 | TGFBR1 (0.81) | TGFBR1MAPK14RIPK2TGFB1KDR | |
| SCHEMBL249408 | 0.90 | TGFBR1 (1.00) | TGFBR1MAPK14RIPK2TGFB1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11857544-B2 | Composition or method including (t)ew-7197 for treating or preventing corneal endothelial diseases | THE DOSHISHA (JP) | 2024-01-02 | — | — | US | claimed |
| US-20230364153-A1 | METHOD FOR DIRECT REPROGRAMMING FROM SOMATIC CELLS INTO PANCREATIC BETA CELLS BY USING MICRORNA, AND DIFFERENTIATION COMPOSITION | Research & Business Foundation Sungkyunkwan University (KR) | 2023-11-16 | — | — | US | claimed |
| US-20230364069-A1 | METHOD FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS THROUGH CO-ADMINISTRATION OF CURCUMIN DERIVATIVE AND TGF-B RECEPTOR INHIBITOR | UNIVERSITY INDUSTRY FOUNDATION, YONSEI UNIVERSITY WONJU CAMPUS (KR) | 2023-11-16 | — | — | US | claimed |
| EP-4248957-A1 | METHOD FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS THROUGH CO-ADMINISTRATION OF CURCUMIN DERIVATIVE AND TGF-? RECEPTOR INHIBITOR | University Industry Foundation, Yonsei University Wonju Campus (KR) | 2023-09-27 | — | — | EP | claimed |
| WO-2022270760-A1 | METHOD FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS THROUGH CO-ADMINISTRATION OF CURCUMIN DERIVATIVE AND TGF-Β RECEPTOR INHIBITOR | 연세대학교 원주산학협력단 | 2022-12-29 | — | — | WO | claimed |
| US-20220186183-A1 | NOVEL GLIA-LIKE CELLS DIFFERENATIATED FROM SOMATIC CELLS, PREPARATION METHOD THEREFOR, COCKTAIL COMPOSITION FOR PREPARING SAME, CELL THERAPEUTIC AGENT FOR PREVENTING OR TREATING NEUROLOGICAL DISORDERS, COMPRISING SAME, AND METHOD FOR PREVENTING AND TREATING NEUROLOGICAL DISORDERS BY ADMINISTERING SAME | Cellapeutics Bio (KR) | 2022-06-16 | — | — | US | claimed |
| WO-2022065859-A1 | METHOD FOR DIRECT REPROGRAMMING FROM SOMATIC CELLS INTO PANCREATIC BETA CELLS BY USING MICRORNA, AND DIFFERENTIATION COMPOSITION | 성균관대학교산학협력단 | 2022-03-31 | — | — | WO | claimed |
| US-20210077476-A1 | COMPOSITION OR METHOD INCLUDING (T)EW-7197 FOR TREATING OR PREVENTING CORNEAL ENDOTHELIAL DISEASES | THE DOSHISHA (JP) | 2021-03-18 | — | — | US | claimed |
| EP-3725313-A1 | COMPOSITION OR METHOD INCLUDING (T)EW-7197 FOR TREATING OR PREVENTING CORNEAL ENDOTHELIAL DISEASES | The Doshisha (JP) | 2020-10-21 | — | — | EP | claimed |
| US-RE47141-E1 | Methods of treating fibrosis, cancer and vascular injuries | EWHA University—Industry Collaboration Foundation (KR) | 2018-11-27 | — | — | US | claimed |
| EP-2588479-B3 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS THERAPEUTIC ALK5 AND/OR ALK4 INHIBITORS | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUND (KR) | 2017-03-29 | — | — | EP | claimed |
| US-20160151451-A1 | METHOD FOR GENERATING CARDIOMYOCYTES | KOREA ADVANCED INST SCI & TECH (KR) | 2016-06-02 | — | — | US | claimed |
| EP-2947081-A1 | 2-Pyridyl substituted imidazoles as therapeutic Alk5 and/or Alk4 inhibitors | Ewha University-Industry Collaboration Foundation (KR) | 2015-11-25 | — | — | EP | claimed |
| EP-2588479-B1 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS THERAPEUTIC ALK5 AND/OR ALK4 INHIBITORS | UNIV EWHA IND COLLABORATION (KR) | 2015-03-04 | — | — | EP | claimed |
| US-8513222-B2 | Methods of treating fibrosis, cancer and vascular injuries | EWHA University—Industry Collaboration Foundation (KR) | 2013-08-20 | — | — | US | claimed |
| EP-2588479-A2 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS THERAPEUTIC ALK5 AND/OR ALK4 INHIBITORS | Ewha University-Industry Collaboration Foundation (KR) | 2013-05-08 | — | — | EP | claimed |
| WO-2012002680-A2 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS THERAPEUTIC ALK5 AND/OR ALK4 INHIBITORS | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2012-01-05 | — | — | WO | claimed |
| US-20110319406-A1 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS THERAPEUTIC ALK5 AND/OR ALK4 INHIBITORS | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2011-12-29 | — | — | US | claimed |
| US-20110319408-A1 | Methods of Treating Fibrosis, Cancer and Vascular Injuries | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2011-12-29 | — | — | US | claimed |
| US-8080568-B1 | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors | EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION (KR) | 2011-12-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319408-A1 | Methods of Treating Fibrosis, Cancer and Vascular Injuries | ACVR1, FLT4, TEK | TGFBR1 8/4885MAPK14 2575/4885RIPK2 1071/4885 |
| US-20220186183-A1 | NOVEL GLIA-LIKE CELLS DIFFERENATIATED FROM SOMATIC CELLS, PREPARATION METHOD THEREFOR, COCKTAIL COMPOSITION FOR PREPARING SAME, CELL THERAPEUTIC AGENT FOR PREVENTING OR TREATING NEUROLOGICAL DISORDERS, COMPRISING SAME, AND METHOD FOR PREVENTING AND TREATING NEUROLOGICAL DISORDERS BY ADMINISTERING SAME | GMFG, HGF, BDNF | TGFBR1 2424/4885MAPK14 2736/4885RIPK2 4480/4885 |
| US-20110319406-A1 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS THERAPEUTIC ALK5 AND/OR ALK4 INHIBITORS | ALK, ACVR1, ACVRL1 | TGFBR1 4/4885MAPK14 776/4885RIPK2 197/4885 |
| US-20210077476-A1 | COMPOSITION OR METHOD INCLUDING (T)EW-7197 FOR TREATING OR PREVENTING CORNEAL ENDOTHELIAL DISEASES | LIPG, TPM3, TEC | TGFBR1 1693/4885MAPK14 702/4885RIPK2 3218/4885 |
| US-20160151451-A1 | METHOD FOR GENERATING CARDIOMYOCYTES | MYLK2, TNNI3, TNNT2 | TGFBR1 3788/4885MAPK14 3373/4885RIPK2 3095/4885 |
| US-20230364069-A1 | METHOD FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS THROUGH CO-ADMINISTRATION OF CURCUMIN DERIVATIVE AND TGF-B RECEPTOR INHIBITOR | TGFBR2, TGFBR1, TGFB1 | TGFBR1 2/4885MAPK14 2519/4885RIPK2 1082/4885 |
| US-11857544-B2 | Composition or method including (t)ew-7197 for treating or preventing corneal endothelial diseases | LIPG, TPM3, TEC | TGFBR1 1693/4885MAPK14 702/4885RIPK2 3218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.